Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies
出版年份 2021 全文链接
标题
Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies
作者
关键词
-
出版物
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 78, Issue 3, Pages 351-363
出版商
Springer Science and Business Media LLC
发表日期
2021-10-28
DOI
10.1007/s00228-021-03242-6
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
- (2021) Zhe Liang et al. Frontiers in Pharmacology
- Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes
- (2020) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
- (2020) Ning Kam et al. PHARMACOECONOMICS
- Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
- (2020) Bhavani Shankara Bagepally et al. BMJ Open Diabetes Research & Care
- Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective
- (2020) Zhe Liang et al. CARDIOVASCULAR DRUGS AND THERAPY
- GRADE guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making
- (2020) Jan L. Brozek et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Cost-Effectiveness of Alirocumab
- (2019) Dhruv S. Kazi et al. ANNALS OF INTERNAL MEDICINE
- Systematic Review and Meta-analysis of Cost-effectiveness of Rotavirus Vaccine in Low and Low-Middle Income Countries
- (2019) Sabbir Haider et al. Open Forum Infectious Diseases
- Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
- (2019) I. Dicembrini et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand
- (2019) Khachen Kongpakwattana et al. PHARMACOECONOMICS
- Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort
- (2019) Alexander Dressel et al. VASCULAR PHARMACOLOGY
- Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
- (2019) Gregg C. Fonarow et al. JAMA Cardiology
- Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects
- (2019) Torbjørn Wisløff et al. ATHEROSCLEROSIS
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
- (2019) Koutaro Yokote et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis
- (2019) Bhavani Shankara Bagepally et al. VALUE IN HEALTH
- Cost-Effectiveness of PCSK9 Inhibitor Plus Statin in Patients With Triple-Vessel Coronary Artery Disease in Japan
- (2018) Satoshi Kodera et al. CIRCULATION JOURNAL
- Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease
- (2018) Manon C. Stam-Slob et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective
- (2018) Radya Kumar et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering
- (2018) Eliano P. Navarese et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis
- (2017) Alessandro Squizzato et al. Internal and Emergency Medicine
- Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
- (2017) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The GRADE Working Group clarifies the construct of certainty of evidence
- (2017) Monica Hultcrantz et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- PCSK9 Inhibitors
- (2017) Mark A. Hlatky et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9 I nhibitors S how Value for Patients and the US Health Care System
- (2017) Wei-Han Cheng et al. VALUE IN HEALTH
- Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context
- (2017) Peter P. Toth et al. JOURNAL OF MEDICAL ECONOMICS
- Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers
- (2017) Alejandro Arrieta et al. JAMA Cardiology
- Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
- (2017) Gregg C. Fonarow et al. JAMA Cardiology
- Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States
- (2016) Shravanthi R. Gandra et al. CLINICAL CARDIOLOGY
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
- (2016) Dhruv S. Kazi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
- (2016) Marian McDonagh et al. Journal of Managed Care & Specialty Pharmacy
- New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism
- (2015) Katsutoshi Miyosawa et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia
- (2015) Eliano Pio Navarese et al. ANNALS OF INTERNAL MEDICINE
- The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
- (2015) Michael J. Lipinski et al. EUROPEAN HEART JOURNAL
- The Limitations of Icers In Screening Interventions and The Relative Net Benefit Alternative
- (2015) JF O’Mahony VALUE IN HEALTH
- Risk of bias in model-based economic evaluations: the ECOBIAS checklist
- (2015) Charles Christian Adarkwah et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials
- (2015) C. Li et al. Journal of the American Heart Association
- Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies
- (2015) Carlos Crespo et al. BMC Medical Research Methodology
- Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Synopsis of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline
- (2014) Neil J. Stone et al. ANNALS OF INTERNAL MEDICINE
- Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
- (2014) S. Matthijs Boekholdt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
- (2011) Gordon Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now